Cassiopea Partners acted as financial advisor to Novamont S.p.A. (“Novamont”) in the redefinition of the shareholder agreement between Mater-Bi S.p.A. and Versalis S.p.A. (“Versalis”), which will also imply an increase of Versalis’ stake in Novamont from 25% to 35%.
Novamont is an international leading company in the bioplastics sector and in the development of biochemicals, operating through three main brands: Mater-Bi, Matrol-Bi and Celus-Bi. In 2020 the company generated revenues for €287m and an EBITDA of €54m.
Within the agreement, Versalis and Novamont will also strengthen their partnership to reinforce synergies in the ecological transition of green chemistry. The commitment to Matrìca – the joint venture set up in 2011 between Versalis and Novamont at Porto Torres specializing in manufacturing bioproducts from renewable sources – has been reconfirmed. The aim is to enhance the company’s technology and production assets in order to fully develop its products. At the end of the reorganization, the ownership structure of Novamont will be configured as follows: Mater-Bi (held by NB Renaissance, Investitori Associati and other private investors) 65% and Versalis 35%.
Cassiopea Partners is very proud of having assisted a world leading player in the biochemicals and bioplastics sector, in the definition of a key strategic solution, leveraging on our deal experience and understanding, seniority and ability to secure high confidentiality. This transaction further reinforces our track record in ESG space.